HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $4.5 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and maintains $4.5 price target.
Jim Cramer Says Forget AT&T, This ‘Class Of The Field’ Communications Stock Is Better
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ADMA Biologics, Inc. (NASDAQ: ADMA) is a "great spec, but it is losing money hand over fist. I think it’s very binary.
HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $4 to $4.5.
Bulls In A Bear Market: These 10 Stocks Clocked Gains In Excess Of 100% In 2022
2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like Apple Inc.
ADMA Biologics Announces Pricing Of Public Offering For $6M Of Common Stock
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's voluntary Chapter 11 petitions filed on November 7.
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers
NexImmune (NASDAQ:NEXI) shares rose 38.8% to $0.7 during Thursday's pre-market session. The market value of their outstanding shares is at $16.9 million.
A Preview Of ADMA Biologics’s Earnings
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that ADMA Biologics will report an earnings per share (EPS) of $-0.08.
Recap: ADMA Biologics Q2 Earnings
ADMA Biologics (NASDAQ:ADMA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.